41. Rammensee HG, Singh-Jasuja H. HLA ligandome tumor antigen discov- ery for personalized vaccine approach. Expert Rev Vaccines 2013; 12(10): 1211–1217. 42. Singh-Jasuja H, Emmerich NP, Ra mmensee HG. The Tubingen approach: identiﬁcation, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 2004; 53(3): 187–195. 43. Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18(8): 1254–1261.